Video

Dr. Zakharia on phase 2 study of durvalumab and RT in urothelial cancer

Author(s):

Urology Times staff

Current Time 0:00
Duration 2:26
Loaded: 0.00%
Stream Type LIVE
Remaining Time 2:26
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Yousef Zakharia, MD, discusses the design and results of a phase 2 trial that explored concurrent treatment with radiation and the PD-L1 inhibitor durvalumab (Imfinzi) followed by adjuvant durvalumab in patients with urothelial cancer. Zakharia is clinical associate professor of internal medicine at the University of Iowa, Holden Comprehensive Cancer Center.

    Related Videos
    Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
    Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
    Study data point to gender disparities in oncology research citations
    Study data point to gender disparities in oncology research citations
    Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
    Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
    Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
    Suzanne B. Merrill, MD, FACS, discusses rBCG and the NMIBC landscape
    Urinary bladder | Image Credit: © magicmine - stock.adobe.com
    Expert describes implications of neoadjuvant durvalumab approval in MIBC
    Sima Porten, MD, on gene-environment interactions in bladder cancer development
    Sima Porten, MD, on gene-environment interactions in bladder cancer development
    3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
    How rBCG EAP could open up access for Anktiva in bladder cancer
    Betty Wang, MD, discusses studies from the 2025 EAU meeting
    Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
    Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
    Joshua J. Meeks, MD, PhD, discusses the impact of neoadjuvant durvalumab approval in MIBC
    Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
    Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
    Related Content
    Sam S. Chang, MD, MBA
    April 28th 2025

    Nogapendekin alfa inbakicept show high CR, avoidance of cystectomy in NMIBC

    Benjamin P. Saylor
    In cohort A, the cystectomy-free rate at 36 months was 84%.
    medical depiction of bladder cancer
    May 31st 2023

    Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

    Urology Times staff
    In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
    Blur image of hospital corridor | Image Credit: © jakkapan - stock.adobe.com
    April 27th 2025

    Estimated DOR of 2 years is seen with UGN-102 in LG-IR-NMIBC

    Benjamin P. Saylor
    The investigators reported that the median Kaplan-Meier estimate of DOR was 24.2 months.
    Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
    December 7th 2021

    Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

    Urology Times staff
    “It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
    Neal D. Shore, MD, FACS
    April 26th 2025

    CREST: Significant EFS boost seen with sasanlimab plus BCG in NMIBC

    Benjamin P. Saylor
    “In the patients with CIS, the probability of a continued complete response at 36 months was 92% vs 67.7%," said Neal D. Shore, MD, FACS.
    3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
    April 26th 2025

    ADVANCED-002: High CR rates observed with TARA-002 in high-grade NMIBC

    Benjamin P. Saylor
    Treatment with TARA-002 was associated with a 100% high-grade CR at any time in BCG-unresponsive participants.
    © 2025 MJH Life Sciences

    All rights reserved.